Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report

Author(s):
Brunet, M.; Gelder, T. van; Asberg, A.; Haufroid, V.; Hesselink, D.A.; Langman, L.; Lemaitre, F.; Marquet, P.; Seger, C.; Shipkova, M.; Vinks, A.; Wallemacq, P.; Wieland, E.; Woillard, J.B.; Barten, M.J.; Budde, K.; Colom, H.; Dieterlen, M.T.; Elens, L.; Johnson-Davis, K.L.; Kunicki, P.K.; MacPhee, I.; Masuda, S.; Mathew, B.S.; Millan, O.; Mizuno, T.; Moes, D.J.A.R. (0000-0003-3219-253X); Monchaud, C.; Noceti, O.; Pawinski, T.; Picard, N.; Schaik, R. van; Sommerer, C.; Vethe, N.T.; Winter, B. de; Christians, U.; Bergan, S.
Published
2019
Publication type
Article / Letter to editor
tacrolimus-personalized therapypharmacokineticsbiomarkerspharmacogeneticspharmacodynamicsconsensusimmunologic biomarkersgraft outcomegraft injurytacrolimus target concentrationsmethods standardizationnew approaches in tacrolimus TDMPopPK/PG modeling
Date issued
2019-06-30
Language
English
Is part of
Therapeutic Drug Monitoring (2019), Vol. 41, no. 3, p. 261-307
hdl
1887/120035
doi
10.1097/FTD.0000000000000640